Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | STAT1 | P42224 | 1/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.59 |
| ▸ | ACP1 | P24666 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295875 | 0.93 | CXCR2 (0.79) | CXCR2DYRK1AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL27093075 | 0.89 | CXCR2 (0.72) | CXCR2DYRK1AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL26034880 | 0.89 | CXCR2 (0.83) | CXCR2DYRK1AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4909104 | 0.88 | CXCR2 (0.76) | CXCR2DYRK1AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL18824178 | 0.86 | DYRK1A (0.57) | CXCR2DYRK1AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL27094626 | 0.86 | CXCR2 (0.69) | CXCR2DYRK1AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL26034876 | 0.84 | CXCR2 (0.77) | CXCR2DYRK1AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL21858369 | 0.84 | CXCR2 (1.00) | CXCR2DYRK1AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL26034882 | 0.84 | CXCR2 (0.76) | CXCR2DYRK1AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL21858373 | 0.82 | KMT2A (0.64) | CXCR2DYRK1AKMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113271941-B | Urea derivatives for the treatment and/or prophylaxis of cancer | 法国国家科学研究中心 | 2024-09-20 | — | — | CN | claimed |
| US-20240199562-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-06-20 | — | — | US | claimed |
| EP-4322944-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Centre National de la Recherche Scientifique (FR) | 2024-02-21 | — | — | EP | claimed |
| WO-2022219123-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-20 | — | — | WO | claimed |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-09 | — | — | US | claimed |
| WO-2020079184-A2 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-04-23 | — | — | WO | claimed |
| CN-113271941-B | Urea derivatives for the treatment and/or prophylaxis of cancer | 法国国家科学研究中心 | 2024-09-20 | — | — | CN | disclosed |
| US-20240199562-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-06-20 | — | — | US | disclosed |
| EP-4322944-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Centre National de la Recherche Scientifique (FR) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022219123-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-20 | — | — | WO | disclosed |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-09 | — | — | US | disclosed |
| CN-113271941-A | Urea derivatives for the treatment and/or prevention of cancer | 法国国家科学研究中心 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020079184-A2 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199562-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | UACA, SLC14A1, MITF | CXCR2 3902/4885DYRK1A 4119/4885KMT2A 2613/4885 |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CXCR1, CXCR2, CXCR6 | CXCR2 2/4885DYRK1A 3903/4885KMT2A 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.